Cargando…
Risk of coronavirus disease 2019 in patients treated for cancer: An immune response–based hypothesis
Autores principales: | Roberto, Michela, Basta, Fabio, Mazzuca, Federica, Curigliano, Giuseppe, Marchetti, Paolo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231735/ https://www.ncbi.nlm.nih.gov/pubmed/32425367 http://dx.doi.org/10.1016/j.ejca.2020.05.003 |
Ejemplares similares
-
The role of stereotactic body radiation therapy in oligometastatic colorectal cancer: Clinical case report of a long-responder patient treated with regorafenib beyond progression
por: Roberto, Michela, et al.
Publicado: (2017) -
Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019
por: Di Cosimo, Serena, et al.
Publicado: (2020) -
The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region
por: Trapani, Dario, et al.
Publicado: (2020) -
Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment
por: Botticelli, Andrea, et al.
Publicado: (2016) -
The Challenge of ICIs Resistance in Solid Tumours: Could Microbiota and Its Diversity Be Our Secret Weapon?
por: Roberto, Michela, et al.
Publicado: (2021)